Preferred Label : hTERT Multipeptide/Montanide ISA-51 VG/Imiquimod Vaccine GX 301;
NCIt definition : A therapeutic cancer vaccine consisting of four epitopes derived from the human telomerase
reverse transcriptase (hTERT), the catalytic subunit of human telomerase, including
hTERT (540-548) acetate, hTERT (611-626) acetate, hTERT (672-686) acetate and hTERT
(766-780) acetate, emulsified individually in the adjuvant montanide ISA-51 VG and
administered with the immune response modifier (IRM) imiquimod, with potential immunostimulating
and antineoplastic activities. Each hTERT peptide emulsion is administered individually
by intradermal injection. Subsequently, imiquimod is applied topically to the injection
site(s). Vaccination with GX 301 may elicit a cytotoxic T-cell (CTL) response against
telomerase-expressing tumor cells. Telomerase is expressed in the majority of human
cancer cells, infrequently expressed in normal cells, and is directly linked to tumorigenesis.
Imiquimod stimulates cytokine production through the activation of toll-like receptor
7 (TLR-7), and also exhibits antiproliferative effects. Montanide ISA-51, also known
as incomplete Freund's adjuvant (IFA), is a stabilized water-in-oil emulsion containing
mineral oil with mannide oleate, which contains vegetable-grade (VG) oleic acid derived
from olive oil. ISA-51 non-specifically stimulates cell-mediated immune responses
to antigens.;
Molecule name : GX 301; GX301;
Origin ID : C119616;
UMLS CUI : C3896843;
Semantic type(s)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
